She sat in the exam room and asked one question. Should I take hormones or not?

It is the wrong question. Not because it is foolish, but because it is far too small for what is actually being decided.

Asking whether to take hormones is like asking whether to take medicine. Which medicine? How much? Delivered how? Made of what? Started when? Every one of those answers moves the risk, and every one of them moves the benefit. Yet most women are handed a yes or a no, as though hormone therapy were a single substance with a single verdict attached.

It is not. Low dose hormone replacement therapy is not simply a smaller version of the old approach. It is a different question entirely, and it deserves a real answer.

The Old Model Asked How Much. The Better Model Asks How Little.

For decades, hormone therapy meant one standard dose of one standard formulation. The Women’s Health Initiative studied exactly that. Conjugated equine estrogen, taken by mouth, paired with a synthetic progestin. One drug, one route, one dose, for everyone.

That is not how the body works, and it is not how physicians who specialize in menopause practice anymore.

Low dose hormone replacement therapy begins from a different premise. Rather than asking how much hormone is standard, it asks how little hormone is sufficient. What is the smallest amount that restores function, quiets symptoms, protects bone, and returns a woman to herself?

This matters because risk in hormone therapy is not a fixed property of estrogen. Risk scales. Higher systemic doses carry greater stroke and clot risk. Lower doses carry less. That relationship holds across delivery methods, which means dose is not a detail buried in the fine print. Dose is the conversation.

Consequently, the phrase “hormones are risky” collapses under its own vagueness. Which hormone? At what dose? Given how? Answer those, and the risk stops being a rumor and starts being a number you can actually weigh.

The Route Changes the Risk Before the Hormone Ever Reaches Your Cells

Here is something almost no woman is told, and it may be the single most useful fact in this entire article.

Estrogen swallowed as a pill travels first to the liver. The liver, encountering a large dose of estrogen, responds by increasing production of clotting factors. That is called first-pass metabolism, and it is where much of the danger in the old model actually lived.

Estrogen absorbed through the skin skips that step entirely. A patch, a gel, or a spray delivers estradiol into the bloodstream without routing it through the liver first. The hemostatic effects are minimal.

The data reflect this. Pooled analyses have found the risk ratio for venous thromboembolism (blood clots) to be roughly 1.9 with oral estrogen and approximately 1.0 with transdermal estrogen. To put that in perspective, a ratio near 1.0 means no detectable increase. Furthermore, a large case-control study found that transdermal estradiol at doses of fifty micrograms per day or less was not associated with increased stroke risk, while oral estrogen was.

Read that again. Same hormone. Different door. Different risk.

This is why women with clotting risk factors, migraine history, or cardiovascular concerns are increasingly steered toward transdermal delivery. It is also why the blanket warnings of 2002, built on oral therapy, never should have been applied to every route.

Your body was designed with pathways. Which pathway you use is not a technicality. It is the difference between two entirely different medicines.

Not All Progesterone Is Progesterone

Now for the second half of the equation, and the place where language has done real harm.

A woman with a uterus who takes estrogen needs a progestogen. Without it, the uterine lining thickens unchecked, and endometrial cancer risk climbs. That is settled and not disputed. The progestogen is protection, not decoration.

But progestogen is a category, not a molecule.

Medroxyprogesterone acetate, the synthetic progestin used in the Women’s Health Initiative, is not the same compound as micronized progesterone. Micronized progesterone is structurally identical to what a woman’s own body produces. Synthetic progestins are not, and they behave differently in breast tissue.

The evidence bears this out. In the E3N cohort, which followed tens of thousands of French women, estrogen combined with synthetic progestins was associated with increased breast cancer risk. Estrogen combined with micronized progesterone was not. A subsequent meta-analysis found a relative risk of roughly 0.67 for progesterone compared to synthetic progestins, meaning a meaningfully lower breast cancer signal.

Yet here is the honest caveat, and I will not skip it. The reassuring data on micronized progesterone comes largely from observational studies covering about five years of use. Longer-term randomized comparisons are still underway. Additionally, some evidence suggests micronized progesterone may protect the endometrium slightly less robustly than certain synthetic progestins, which is precisely why dosing and monitoring matter.

So the truthful statement is this. Micronized progesterone appears to carry a more favorable breast profile, the evidence is good but not yet complete, and your physician needs to be watching your lining regardless.

That is a far more useful sentence than either “progesterone is safe” or “hormones cause cancer.”

The Most Underused Therapy in Women’s Health

If you take nothing else from this article, take this.

Local vaginal estrogen is not systemic hormone therapy. It is applied directly to the tissue that needs it, in doses so small that systemic absorption is minimal to negligible. The ultra-low dose vaginal tablet delivers ten micrograms. The lower-dose ring releases roughly seven and a half micrograms daily. These are fractions of a fraction.

Meanwhile, what it treats is enormous. Vaginal dryness. Painful intimacy. Burning. Urinary urgency. Recurrent urinary tract infections, which in older women can escalate into hospitalization and sepsis. Genitourinary syndrome of menopause affects an extraordinary number of women, and unlike hot flashes, it does not fade with time. It progresses.

Local vaginal estrogen is strongly recommended for women with recurrent urinary tract infections. Large cohort data, including the Nurses’ Health Study, found no association between vaginal estrogen use and higher cardiovascular disease or cancer risk. In November of 2025, the FDA removed the black box warning from vaginal estrogen products, acknowledging what researchers had been saying for years. That warning had been extrapolated from systemic therapy trials involving vastly higher exposure.

Millions of women have suffered silently, for decades, because a warning meant for something else was stamped on the package of something safe.

That is not a small failure. That is a generation of women told to accept pain that had a treatment sitting on a pharmacy shelf.

The Bioidentical Trap

Now I have to tell you something you may not want to hear, because this is where women in our community get taken advantage of.

The word “bioidentical” has been split into two very different things, and one of them is being marketed to you dishonestly.

FDA-approved bioidentical hormones are real. Estradiol patches and gels contain bioidentical estradiol. Micronized progesterone capsules contain bioidentical progesterone. These are tested, standardized, and consistent from dose to dose. When menopause specialists talk about the safety advantages of bioidentical hormones, these are what they mean.

Compounded bioidentical hormone therapy is a different animal. These are custom preparations mixed by compounding pharmacies, and they are not FDA-approved. Studies analyzing the actual content of compounded capsules and creams have found variability in potency. The Endocrine Society has documented risks of overdosing, underdosing, and contamination. ACOG (American College of Obstetricians and Gynecologists) recommends against prescribing compounded bioidentical hormone therapy routinely when FDA-approved formulations exist.

Hormone pellets deserve their own warning. ACOG explicitly discourages them, in part for a reason that should stop you cold. Once a pellet is implanted, it cannot be removed. If the dose is wrong, you wait it out.

Additionally, salivary hormone testing used to justify custom dosing is not a validated method for guiding menopausal hormone therapy. It sounds precise. It is not.

I am telling you this because the natural health world is full of people who will sell you fear about pharmaceutical estrogen and then hand you an unregulated compound at four times the price. Discernment cuts in both directions. It does not spare the marketing you happen to agree with.

Ask the Better Question

You do not need to become a pharmacologist. You need to walk into that room with a better question than the one you were handed.

Not “should I take hormones.” Instead: What dose, in what form, by what route, and why that one for me?

Ask

• Whether transdermal makes sense given your clotting history.
• Whether micronized progesterone is an option.
• Ask about local vaginal estrogen if that is where your symptoms live, even if you want nothing else.
• Ask why, and expect an answer that fits you, rather than a category.

Some women, after all of that, will decide hormone therapy is not for them. That is a legitimate answer, and it is theirs to make. What is not legitimate is having the decision made for you by a headline, a marketing funnel, or a doctor who has not updated since 2002.

YHVH gave you a body that speaks in signals and a mind capable of weighing them without panic. You are not too old to ask. You are not too late to learn. And you are certainly not obligated to suffer in a silence someone else assigned you.

Go ask the better question.

For the full picture of how this season affects the whole body, this guide to menopause and whole-person wellness covers hormones, symptoms, and healthy aging in one place.

Continue the Journey

Ready to go deeper? These resources will meet you where you are.

If your symptoms are tangled up with stress and you cannot tell where one ends and the other begins, RISE: Healing From the Inside Out, Volume 3 works at the layer beneath behavior, where hormones and the nervous system actually meet.

If your body has stopped feeling like an ally, RISE: Body Trust, Movement, & Mindful Strength, Volume 2 helps you rebuild the conversation. Your body was never the enemy. It was faithful.

If you are being marketed to from every direction and need your footing back, RISE™ Identity & Worth, Volume 1 grounds you in something steadier than the loudest voice in the room.

If you want the framework that holds all of this together, RISE: The Beginning of Balance is the place to begin.

Are you ready to return to the Creator’s original design for your body? The Eden Way will walk you back.

And if you need scripture to steady you while you sort through hard decisions, Psalms of Rooting gives you words to hold.

A Reading List for This Journey

• The Cyclospora Parasite: Facts, Fear, and Fresh Produce — the same pattern of fear outrunning facts
• Healing From the Inside Out Is Here, And It Was Written for You
• Dopamine Hijacks: The Overlap of Food and Technology
• Habit Stacking for Better Health: Small Daily Changes
• Randall King Mental Health Break and Its Importance
• Your Garden as a Parable: Lessons from Nature
• Browse the full Body and High Cortisol collections

---

More in This Series

If this article spoke to you, it is part of a five-part series on menopause, hormones, and what nobody explained clearly enough. Each one stands alone, but together they tell the whole story.

• Hormone Replacement Therapy Cancer Risk: What the Headlines Got Wrong — how the 2002 reporting scared a generation away from treatment, and what the numbers actually said.
• Menopause and Nerve Pain: Why the Burning Starts Twenty Years Later — the delayed nerve symptoms nobody connects to menopause, and what to rule out first.(Publishing 10/12/2026)
• Wild Yam Cream: What It Actually Does, and the One Thing It Cannot Do — why the popular natural progesterone claim does not hold, and who it puts at risk. (Publishing 10/26/2026)
• Menopause and Blood Sugar: Why Your Numbers Changed When Nothing Else Did — the estrogen and insulin connection, and why the shift is hormonal, not a failure of willpower. (Publishing 11/9/2026)

Even More

• Peripheral Neuropathy Recovery: My Sister’s Testimony of Hope For twenty years, my sister lived with severe peripheral neuropathy. She was told the damage was permanent and that all she could do was manage the pain. She refused to accept that answer. (Publishing 11/23/2026)

• Being Your Own Health Advocate: My Sister’s Powerful Example What do you do when doctor after doctor tells you, “There’s nothing more we can do”? My sister faced that question for nearly twenty years. (Publishing 12/7/2026)
• Red Clover and Hops: Gentle Menopause Help and Honest Concerns Menopause sends so many of us searching the supplement shelf at midnight. Red clover and hops both promise gentle, natural relief. But do they truly help, and are they safe for your body? (Publishing 12/21/2026)
• Doing Your Own Health Research: How to Dig Deep Without Getting Lost Have you ever left a doctor’s office with more questions than answers? Then found yourself deep in a research rabbit hole past midnight? You are not alone, and you are not wrong to seek. (Publishing 1/4/2027)
• The Truth About Progesterone: Real Science vs. a Sales Pitch A sales pitch for a topical cream with added hormones arrived in my inbox. In this article we examine the hype and search for the truth. (Publishing January 18, 2027)

Come sit with us. The RISE with Momentum Circle gathers weekly, and there is room at the table for your questions.

The right dose of truth is all of it. Anything less is just a smaller lie.

Healthy Living Picks

Walking into a hormone conversation prepared makes all the difference. Over on my Amazon Storefront, I keep a curated collection of books, kitchen tools, and wellness resources I actually use, including titles on women’s health, bone strength, and whole-food plant-based living to support your foundation while you sort the rest out.

Have a look when you have a quiet moment. Everything there is something I would hand to a friend.

As an Amazon Associate, I earn from qualifying purchases.

References

1. Canonico M, Oger E, Plu-Bureau G, et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi:10.1161/CIRCULATIONAHA.106.642280. PMID: 17309934. (Oral but not transdermal estrogen raised VTE risk.)
2. Scarabin PY, Oger E, Plu-Bureau G; ESTHER Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–432. doi:10.1016/S0140-6736(03)14066-4. PMID: 12927428. (The earlier transdermal-vs-oral VTE finding.)
3. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–1231. doi:10.1136/bmj.39555.441944.BE. PMID: 18495631. (Pooled route-of-administration risk estimates.)
4. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111. doi:10.1007/s10549-007-9523-x. PMID: 17624588. (RR ~1.4 synthetic progestins vs ~0.9 micronized progesterone.)
5. The North American Menopause Society. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. PMID: 35797481. (Vaginal estrogen safety; local low-dose therapy guidance.)
6. Ackerman AL, Bradley M, D’Anci KE, et al. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2025. doi:10.1097/JU.0000000000004723. (Vaginal estrogen recommended for recurrent UTIs.)
7. American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Committee Opinion No. 532 (reaffirmed). Available at acog.org. (Recommends against routine compounded bioidentical hormones and discourages pellets.)
8. U.S. Food and Drug Administration. HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy. FDA news release; November 10, 2025. fda.gov/news-events/press-announcements
9. Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. Published online November 10, 2025. doi:10.1001/jama.2025.22259

Important Nuances

The specific figure that ~10 mcg vaginal tablets and ~7.5 mcg/day rings produce minimal systemic absorption comes from product labeling and the NAMS position statement (refs 5, 8) rather than a single standalone trial.

ACOG applauded the vaginal-estrogen change specifically, but some clinicians and outlets have pushed back that the systemic-estrogen benefits are being overstated and the breast cancer nuance flattened.